Journal
VACCINE
Volume 28, Issue 13, Pages 2497-2504Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.01.038
Keywords
Immunotherapy; Dendritic cell vaccine; Chronic hepatitis B
Categories
Funding
- Taizhou Hepatopathy Centre
- Shaanxi Biologic Diagnosis and Therapy Engineering Research Center
- State Key Laboratory of Cancer Biology
- Ministry of Science and Technology of the People's Republic of China
- National Natural Science Foundation of China
Ask authors/readers for more resources
Antigen-presenting autologous dendritic cells (ADCs), primed with antigen, have been used in immunotherapy. We evaluated ADCs for treatment of chronic hepatitis B (CHB). ADCs were administered to 380 CHB patients. Virological, biochemical, and serological responses were evaluated in each patient over the course of 48 weeks. Undetectable levels of HBV DNA were reported in 46.36% of patients negative for the hepatitis B e antigen (HBeAg) and 3.13% HBeAg-positive patients. Normalization of alanine aminotransferase levels occurred in both HBeAg-positive (P=0.007) and HBeAg-negative (P=0.003) patients. It appears that ADC vaccination effectively reconstructed the immunity and elicited virological, serological, and biochemical improvements in some patients with chronic HBV. No side effects were observed. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available